Trial Profile
FDG-PET/MRI imaging for the evaluation of early response to nivolumab in patients with previously treated non-small cell lung cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 05 Jun 2020
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 03 Jun 2020 Status changed from active, no longer recruiting to completed.
- 31 May 2018 Status changed from recruiting to active, no longer recruiting.
- 15 Jan 2017 Planned number of patients changed from 15 to 25.